Sanofi Consumer Healthcare India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2025 ,inter alia, to consider and approve Unaudited ....

Revenue growth above 20%Profit growth above 25%EBITDA margin compressionResults View source PDF Explain this filing

SANOFICONR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.1%Reaction day

₹4860.40

prior close

₹4800.00

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-1.7%-1.4% vs market

Pharmaceuticals peers, median of 156sector-1.1%-2.0% vs sector

On the reaction day the stock moved 1.4 pts less than Nifty Microcap 250 and 2.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.5

10m

+0.4

15m

+0.3

30m

+0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.1-1.7-1.4-1.1-2.0

Next day

-4.7-1.3-3.4-1.4-3.3

-4.7-1.7-3.0-2.0-2.7

-5.4-1.9-3.5-2.3-3.2

-4.5-1.0-3.5-1.2-3.3

+2.8-1.1+3.9-1.7+4.4

-2.2-0.6-1.6-1.7-0.5

15d

-2.6-3.0+0.4-4.3+1.7

-4.5-8.1+3.6-7.0+2.4

-9.3-4.8-4.5-5.1-4.3

-12.4-9.1-3.3-8.9-3.6

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 156Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Sanofi Consumer Healthcare India has informed the stock exchanges that its Board of Directors will meet on Wednesday, 12 November 2025. The main agenda is to consider and approve the Unaudited Financial Results for the quarter and nine months ended 30 September 2025. The company has also confirmed that the trading window for designated persons remains closed from 1 October 2025 to 14 November 2025 in line with its insider trading code. This is a routine regulatory filing under SEBI Listing Regulations, and no financial numbers have been disclosed in this intimation.

Likely market impact

No direct impact on the stock from this filing as it only notifies an upcoming board meeting. Investors should watch for the actual Q2 FY26 results on or after 12 November 2025 for insights into revenue, profit and margins. The closed trading window means insiders cannot trade until after results are published.

By the numbersStandalone · Q2 FY26 vs Q2 FY25

	Q2 FY26	Q2 FY25	Change
Revenue	₹233.9 Cr	₹159.9 Cr	+46.3%
Operating profit	₹81.10 Cr	₹58.20 Cr	+39.3%
Profit after tax	₹62.90 Cr	₹45.00 Cr	+39.8%
EBITDA margin	36.3%	38.7%	−2.4 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.